Endocrine Testing Market by Type (Thyroid, Insulin, HCG, Prolactin, Progesterone, LH, FSH), Technology (Immunoassay, Tandem Mass Spectroscopy, Clinical Chemistry), End User (Hospitals, Clinical Laboratories) - Global Forecast to 2027
Increasing prevalence of thyroid issues, diabetes and other hormonal issues are pushing the growth of the Endocrine Testing Market.
The global Endocrine Testing Market is expected to reach USD xx billion by 2027 from USD xx billion in 2022, at a CAGR of xx%. The growth in this market is driven by the increasing prevalence of the endocrine disorders such as thyroid imbalance, diabetes, Polycystic Ovary Syndrome, etc. Also, the increasing government funding and rising awareness for the endocrine hormone tests for the diagnosis and management of the endocrine disorder have also fueled the growth of the market.
To know about the assumptions considered for the study, Request for Free Sample Report
“The solutions segment held the largest market share in 2021.”
Based on type, the Endocrine Testing Market is segmented into thyroid test, insulin test, human chorionic gonadrotrophin test, prolactin test, luteinizing test, Progesterone, Estradiol (E2), Follicle Stimulating Hormone (FSH) test, Dehydroepiandrosterone sulfate (DHEAS) test, Testosterone Test, Cortisol Test, and other tests. The insulin segment held the largest share in 2021, which is driven by the high volume of insulin tests, high prevalence of diabetes.
“The immunoassay segment is accounted for the largest share in 2021.”
Based on the technology, the Endocrine Testing Market is segmented into immunoassay, tandem mass spectroscopy, clinical chemistry and other technology. The immunoassay segment is held the largest share owing to its wider usage for the diagnosis and quantitation of endocrine hormones or proteins. High precision, and low detection limits.
“Asia Pacific is estimated to register the highest CAGR during the study period. North America is expected to dominate the market share”
In this report, the Endocrine Testing Market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and Rest of the World. North America to dominate the market in 2021, owing to its advanced testing technologies, massive volume of endocrine testing, and increasing prevalance of endocrine disorders such as diabetes, thyroid issues, and other hormonal issues. The increasing awarenss and government programs and support for the endocrine testing are also promoting the market growth.
Asia Pacific Market is expected to grow at the fastest CAGR during the forecast period of 2022 to 2027, this is attributed to the vast geriatric popualtion, expaniding population base, huge volume of endocrine testing due to the massive prevalance of endorcine diroders such as diabetes, hyperthyroidism, hypothyroidism, etc.
Breakdown of primary supply-side interviews, by company type, designation, and region:
- By Company Type - Tier 1: 48%, Tier 2: 40%, and Tier 3: 12%
- By Designation - C-level: 44%, D-level: 30%, and Others: 26%
- By Region: North America (34%), Europe (26%), AsiaPacific (23%), and Rest of the World (17%)
To know about the assumptions considered for the study, download the pdf brochure
List of Companies Profiled in the Report
- Abbott Laboratories
- AB Sciex
- Agilent Technologies
- bioMerieux SA
- Bio Rad Laboratories
- LabCorp
- Quest Diagnostics
- F. Hoffmann-La Roche AG
- Siemens Healthcare
- Thermo Fisher Scientific
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED FOR THE STUDY
1.5 CURRENCY
1.6 LIMITATIONS
1.9 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 KEY DATA FROM PRIMARY SOURCES
2.4 MARKET SIZE ESTIMATION
2.4.1 BOTTOM-UP APPROACH
2.4.2 GROWTH FORECAST
2.4.3 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 PRICING ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5 PORTER FIVE FORCES ANALYSIS
5.7 REGULATORY LANDSCAPE
5.8 TECHNOLOGY ANALYSIS
5.8 TRADE DATA ANALYSIS
5.9 PATENT ANALYSIS
6 ENDOCRINE TESTING MARKET, BY TYPE
6.1 INTRODUCTION
6.2 THYROID TEST
6.3 INSULIN TEST
6.4 HUMAN CHORIONIC GONADOTROPIN TEST
6.5 PROLACTIN TEST
6.6 LUTEINIZING HORMONE TEST
6.7 PROGESTERONE TEST
6.8 ESTRADIOL (E2) TEST
6.9 FOLLICLE STIMULATING HORMONE(FSH) TEST
6.10 DEHYDROEPIANDROSTERONE SULFATE (DHEAS) TEST
6.11 TESTOSTERONE TEST
6.12 CORTISOL TEST
6.13 OTHER TESTS
7 ENDOCRINE TESTING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 IMMUNOASSAY
7.3 TANDEM MASS SPECTROSCOPY
7.4 CLINNICAL CHEMISTRY
7.5 OTHER TECHNOLOGY
8 ENDOCRINE TESTING MARKET, END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 CLINICAL LABORATORIES
8.4 OTHERS
9 ENDOCRINE TESTING MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 REST OF ASIA PACIFIC
9.5 REST OF THE WORLD
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET SHARE/RANKING ANALYSIS, 2019
10.3 COMPETITIVE SCENARIO
10.3.1 PRODUCT LAUNCHES AND APPROVALS
10.3.2 PARTNERSHIPS, COLLABORATIONS, MERGERS, AND AGREEMENTS
10.3.3 EXPANSIONS
10.3.4 ACQUISITIONS
10.3.5 OTHER DEVELOPMENTS
10.4 COMPETITIVE LEADERSHIP MAPPING (2019)
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE
10.4.4 PARTICIPANTS
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 INTRODUCTION
11.2 ABBOTT LABORATORIES
11.3 AB SCIEX
11.4 AGILENT TECHNOLOGIES
11.5 BIOMERIEUX SA
11.6 BIO RAD LABORATORIES
11.9 LABCORP
11.9 QUEST DIAGNOSTICS
11.9 F. HOFFMANN-LA ROCHE AG
11.10 SIEMENS HEALTHCARE
11.11 THERMO FISHER SCIENTIFIC
11.12 SYSMEX CORPORATION
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS OF INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
Growth opportunities and latent adjacency in Endocrine Testing Market